Metastatic breast cancer, version 1.2012: Featured updates to the NCCN guidelines

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 10, Issue 7, 2012, Pages 821-829

  Carlson, Robert W ^a   Allred, D Craig ^b   Anderson, Benjamin O ^c   Burstein, Harold J ^d   Edge, Stephen B ^e   Farrar, William B ^f   Forero, Andres ^g   Giordano, Sharon Hermes ^h   Goldstein, Lori J ⁱ   Gradishar, William J ^j   Hayes, Daniel F ^k   Hudis, Clifford A ^l   Isakoff, Steven Jay ^m   Ljung, Britt Marie E ⁿ   Mankoff, David A ^c   Marcom, P Kelly ^o   Mayer, Ingrid A ^p   McCormick, Beryl ^l   Pierce, Lori J ^k   Reed, Elizabeth C ^q   Smith, Mary Lou ^r   Soliman, Hatem ^s   Somlo, George ^t   Theriault, Richard L ^h   Ward, John H ^u   Wolff, Antonio C ^v   Zellars, Richard ^v   Kumar, Rashmi ^w   Shead, Dorothy A ^w   more..

^a STANFORD CANCER INSTITUTE   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

^c SEATTLE CANCER CARE ALLIANCE   (United States)

^d DANA FARBER BRIGHAM AND WOMEN S CANCER CENTER   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ FOX CHASE CANCER CENTER   (United States)

^j NORTHWESTERN UNIVERSITY   (United States)

^k UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^m MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o DUKE CANCER INSTITUTE   (United States)

^p VANDERBILT INGRAM CANCER CENTER   (United States)

^q NEBRASKA MEDICAL CENTER   (United States)

^r Media Relations and Special Projects   (United States)

^s H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^t CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^u UNIVERSITY OF UTAH   (United States)

^v JOHNS HOPKINS UNIVERSITY   (United States)

^w National Comprehensive Cancer Network   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EVEROLIMUS; EXEMESTANE; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; TEMSIROLIMUS;

ALGORITHM; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; DECREASED APPETITE; DIARRHEA; DISEASE ACTIVITY; DRUG ERUPTION; FATIGUE; HUMAN; HYPERGLYCEMIA; METASTASIS; OVERALL SURVIVAL; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; POSTMENOPAUSE; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; REVIEW; SIGNAL TRANSDUCTION; STOMATITIS;

EID: 84865341798     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2012.0086     Document Type: Review

References (18)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Allred DC, Carlson RW, Berry DA, et al. NCCN Task Force Report: estrogen receptor and progesterone receptor testing in breast bancer by immunohistochemistry. J Natl Compr Canc Netw 2009;7(Suppl 6):S1-21.
3. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784-2795.
4. Carlson RW, Moench SJ, Hammond ME, et al. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 2006;4(Suppl 3):S1-22.
5. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145.
6. Bogina G, Bortesi L, Marconi M, et al. Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss. Virchows Arch 2011;459:1-10.
7. Fabi A, Di Benedetto A, Metro G, et al. HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Clin Cancer Res 2011;17:2055-2064.
8. Karlsson E, Lindström LS, Wilking U, et al. Discordance in hormone receptor status in breast cancer during tumor progression [abstract]. J Clin Oncol 2010;28:(Suppl):Abstract 1009.
9. Sari E, Guler G, Hayran M, et al. Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer. Med Oncol 2011;28:57-63.
10. Simmons C, Miller N, Geddie W, et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 2009;20:1499-1504.
11. Gong Y, Booser DJ, Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 2005;103:1763-1769.
12. Tapia C, Savic S, Wagner U, et al. HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res 2007;9:R31.
13. Bergh J, Jönsson P, Lidbrink E, et al. First results from FACT - an open-label, randomized phase III study investigating loading dose of fulvestrant combined with anastrozole versus anastrozole at first relapse in hormone receptor positive breast cancer [abstract]. Cancer Res 2009;69(24 Suppl):Abstract 23.
14. Mehta R, Barlow W, Albain K, et al. A Phase III randomized trial of anastrozole versus anastrozole and fulvestrant as first-line therapy for postmenopausal women with metastatic breast cancer: SWOG S0226 [abstract]. Presented at the 34th Annual San Antonio Breast Cancer Symposium; December 6-10, 2011; San Antonio, Texas. Abstract 1.
15. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
16. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-214.
17. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-529.
18. Chow L, Sun Y, Jassem J, et al. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer [abstract]. Presented at the 29th Annual San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, Texas. Abstract 6091.